IMMUNOPROPHYLAXIS OF PSEUDOMONOSIS: ACHIEVEMENTS AND PERSPECTIVES

The review article presents a retrospective analysis of attempts to develop effective vaccines for pseudomonas prophylaxis. P. aeruginosa vaccine has been sought for 40 years; however it is still not available. The increased understanding of P. aeruginosa pathogenesis and its virulence factors supported the recognition of potential immunogens and passive immunotherapy that could be used for the development of an effective vaccine. These immunogens are situated in structural components such as lipolysaccharides, pili, flagella, outer membrane proteins or are part of secreted products such as proteases, exotoxins and mucoid exopolysaccharides. There have been significant advances in later years; nonetheless there is clear need for additional basic research to further increase the understanding of those elements of immune response to P. aeruginosa. Recently, the antigenic drift of the P. aeruginosa actual strains has changed significantly, and no one has studied such changes in Ukraine, despite the high mortality from pseudomonas in the intensive care unit. The development of a multi-strain vaccine based on the actual strains of P. aeruginosa, in our opinion, can significantly reduce the formation of nosocomial circulation of multidrug-resistant strains, and contribute to reducing morbidity and mortality rates from nosocomial pseudomonosis